NEW YORK (GenomeWeb) – OncoCyte said today that its net loss rose about 60 percent in Q1 2017 compared to the same quarter in 2016, but it believes it is on track to launch its first test for lung cancer later this year.

The liquid biopsy firm's net loss for the three months ended March 31, 2017 was $4.7 million, or $0.16 per share, compared to a loss of $2.9 million, or $0.12 per share, for the prior year's first quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.